Phase III, multicenter, randomized, double-blind, placebo-controlled study of norursodeoxycholic acid in metabolic dysfunction-associated steatotic liver disease patients.

Fibrosis improvement was observed in 57% of norUDCA-treated vs 40% in placebo-treated ( P = 0.035), with highly significant adjusted mean ( P = 0.002). nonalcoholic fatty liver disease fibrosis score at week 18 and 24 ( P = 0.041 and P = 0.032).

also in 132,142 other papers

Lipid profile and HbA1c A favorable trend with reductions in lipid parameters, including total cholesterol, high-density lipoprotein, low-density lipoprotein, and triglycerides was observed with norUDCA treatment, HbA1c levels remained relatively stable in both groups.

also in 1,335 other papers